Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We investigated the prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) in patients with head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoint inhibitors (ICIs). We systematically searched electronic databases and identified articles reporting an association between NLR and treatment results in patients with HNSCC treated with ICIs. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) and odds ratios (ORs) for response and disease control were extracted. Pooled HRs and ORs were estimated using random-effects models. Fourteen studies involving 929 patients were included. A higher NLR was associated with poor OS (HR 2.03, 95% confidence interval [CI] 1.50-2.74), PFS (HR 2.15, 95% CI 1.44-3.21), response (OR 0.49, 95% CI 0.26-0.93), and disease control (OR 0.30, 95% CI 0.12-0.74). The NLR predicts treatment results with ICIs in patients with HNSCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.26997 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The assessment of the fibrinogen-to-platelet ratio for predicting mortality of COVID-19 in non-diabetic subjects.
Int J Environ Health Res
September 2025
Department of Research, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Instituto Mexicano del Seguro Social (IMSS), Veracruz, Mexico.
Little is known about the biomarkers of mortality in SARS-CoV-2-infected patients without a previous diagnosis of diabetes. Thus, this study aimed to assess the fibrinogen-to-platelet ratio (FPR) and compare its predictive value with the main biomarkers for COVID-19 mortality, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), leukocyte glucose index (LGI), and lactate dehydrogenase (LDH)/lymphocyte ratio. This retrospective cohort study in a population of Mexico included 70 non-diabetic patients with COVID-19 from 1 May 2020 to 30 September 2020.
View Article and Find Full Text PDFThe relationship among inflammatory biomarkers, hyperuricemia and chronic kidney disease: analysis of the NHANES 2015-2020.
Ren Fail
December 2025
Department of Nephrology, The First Hospital of Jilin University, Changchun, China.
Background: Inflammation and hyperuricemia are closely associated with chronic kidney disease (CKD). The systemic inflammation response index (SIRI), systemic immune-inflammation index (SII), monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are emerging as novel biomarkers. While, the synergistic effects of these biomarkers with hyperuricemia on CKD remain unclear.
View Article and Find Full Text PDFImmunoglobulin free light chain-κ in association with NT-proBNP levels after smoking cessation.
Future Sci OA
December 2025
Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Background: Smoking induces inflammation in the heart and intima layer of blood vessels by activating nuclear factor kappa B, which controls the transcription of immunoglobulin free light chain (FLC)-κ. FLC levels are indicative of higher mortality in the overall population and poorer prognoses in cardiovascular diseases. This study aimed to analyze the effect of smoking cessation (SC) on the levels of FLCs and markers of inflammation and heart failure.
View Article and Find Full Text PDFPrognostic role of the baseline neutrophil‒eosinophil ratio in cancer patients: a meta-analysis and systematic review.
World J Surg Oncol
September 2025
Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Background: Inflammation impacts the prognosis of numerous types of tumors. Inflammatory indicators such as the neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and neutrophil-to-eosinophil ratio (NER) have emerged as potential prognostic markers and are closely correlated with the outcomes of cancer patients. However, the connection between NER and cancer prognosis remains incompletely understood.
View Article and Find Full Text PDFAims: This study aimed to evaluate the therapeutic efficacy of durvalumab and tremelimumab (Dur/Tre) in patients with hepatocellular carcinoma (HCC) who had a tumor thrombus in the main portal vein trunk (Vp4) or high tumor burden (HTB).
Methods: A total of 309 patients with BCLC stage B or C HCC who received Dur/Tre between March 2023 and October 2024 were included. HTB was defined as the presence of at least one of the following radiological findings: ≥ 50% liver involvement by HCC, bile duct invasion, or the presence of Vp4.